Literature DB >> 12467693

Chronicle of an outbreak foretold: meningococcal meningitis W135 in Burkina Faso.

Josef Decosas1, Jean-Baptiste T Koama.   

Abstract

Burkina Faso lies within the African meningitis belt. Until recently, serogroup A of Neisseria meningitidis was the most common cause of epidemic meningitis in Burkina Faso. However, during the epidemic that started in January 2002, W135 was the predominant serogroup of meningococcus. Vaccine against the W135 serogroup is expensive and in short supply. Strategies to react to a future African epidemic of W135 meningococcal meningitis with a sufficient and affordable supply of vaccine must be put into place now.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12467693     DOI: 10.1016/s1473-3099(02)00455-3

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN: 1473-3099            Impact factor:   25.071


  28 in total

Review 1.  Epidemiology, diagnosis, and antimicrobial treatment of acute bacterial meningitis.

Authors:  Matthijs C Brouwer; Allan R Tunkel; Diederik van de Beek
Journal:  Clin Microbiol Rev       Date:  2010-07       Impact factor: 26.132

2.  Preparedness for infectious threats: public-private partnership to develop an affordable vaccine for an emergent threat: the trivalent Neisseria meningitidis ACW135 polysaccharide vaccine.

Authors:  Christopher B Nelson; Maureen Birmingham; Alejandro Costa; Joelle Daviaud; William Perea; Marie-Paule Kieny; Daniel Tarantola
Journal:  Am J Public Health       Date:  2007-04-05       Impact factor: 9.308

3.  The changing face of meningococcal disease in West Africa.

Authors:  B Greenwood
Journal:  Epidemiol Infect       Date:  2007-07       Impact factor: 2.451

4.  Evidence for capsule switching between carried and disease-causing Neisseria meningitidis strains.

Authors:  Amanda J Beddek; Ming-Shi Li; J Simon Kroll; T William Jordan; Diana R Martin
Journal:  Infect Immun       Date:  2009-05-18       Impact factor: 3.441

Review 5.  Prospects for vaccine prevention of meningococcal infection.

Authors:  Lee H Harrison
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

6.  Conjugates of group A and W135 capsular polysaccharides of neisseria meningitidis bound to recombinant Staphylococcus aureus enterotoxin C1: preparation, physicochemical characterization, and immunological properties in mice.

Authors:  Zhigang Jin; Gregory A Bohach; Joseph Shiloach; Scott E Norris; Darón I Freedberg; Claudia Deobald; Bruce Coxon; John B Robbins; Rachel Schneerson
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

7.  Biochemical and biophysical characterization of the sialyl-/hexosyltransferase synthesizing the meningococcal serogroup W135 heteropolysaccharide capsule.

Authors:  Angela Romanow; Thomas Haselhorst; Katharina Stummeyer; Heike Claus; Andrea Bethe; Martina Mühlenhoff; Ulrich Vogel; Mark von Itzstein; Rita Gerardy-Schahn
Journal:  J Biol Chem       Date:  2013-02-25       Impact factor: 5.157

Review 8.  Vaccine prevention of meningococcal disease in Africa: Major advances, remaining challenges.

Authors:  Mustapha M Mustapha; Lee H Harrison
Journal:  Hum Vaccin Immunother       Date:  2018-01-16       Impact factor: 3.452

9.  Development of a glycoconjugate vaccine to prevent meningitis in Africa caused by meningococcal serogroup X.

Authors:  Francesca Micoli; Maria Rosaria Romano; Marta Tontini; Emilia Cappelletti; Massimiliano Gavini; Daniela Proietti; Simona Rondini; Erwin Swennen; Laura Santini; Sara Filippini; Cristiana Balocchi; Roberto Adamo; Gerd Pluschke; Gunnstein Norheim; Andrew Pollard; Allan Saul; Rino Rappuoli; Calman A MacLennan; Francesco Berti; Paolo Costantino
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-04       Impact factor: 11.205

10.  Meningococcal disease and climate.

Authors:  Helena Palmgren
Journal:  Glob Health Action       Date:  2009-11-11       Impact factor: 2.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.